Market Size of Global Erythropoietin Stimulating Agents Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Erythropoietin Stimulating Agents Market Analysis
The erythropoietin stimulating agents (ESAs) market was valued at approximately USD 8,223 million in 2020 and is expected to witness a revenue of USD 13,436 million in 2026, with a CAGR of 8.6% over the forecast period.
According to a research study published in the American Journal of Kidney Disease, 2020, among the patients with COVID-19, with or without Acute Kidney Injury(AKI) and anemia, ESAs should be avoided in the therapy, as these patients are unlikely to mount an effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits. Hence, the COVID-19 pandemic is expected to severely impact the studied market growth during the pandemic.
The ESAs market is driven by an increasing number of patients suffering from anemia, increasing applications in HIV infections and end-stage renal disorder, risks of thrombosis during surgeries, and pure red cell aplasia.
Anemia has been one of the serious nutrition-related diseases over the past few decades and is the major reason for increased morbidity and mortality, especially in low and middle-income countries. According to a research article published in PLoS One, 2019, Anemia is estimated to affect nearly 1.62 billion people worldwide and the prevalence of anemia was found to be 41.1% in Ethiopia. Additionally, as per the Lancet Global Health, 2019, India is estimated to account for nearly one-quarter of the global anemia cases. Iron Deficiency Anemia is common in children and women and is associated with sensory, motor, cognitive, language, and socioemotional deficits. Hence, the early detection and initiation of effective treatment strategies in the early stages of anemia are very important, especially among infants.
Other causes of anemia include parasite infections, such as ascaris, schistosomiasis, and hookworms, which can lower the hemoglobin (Hb) concentration in blood, along with heavy blood loss during menstruation among women.
Additionally, as per the Centers for Disease Control and Prevention's (CDC) 2019 report, it was estimated that about 37 million (15%) of the adult population in the United States had chronic kidney disease (CKD), which increases the severity of anemia. Therefore, as the number of people affected by anemia increases, the demand for erythropoietin stimulating agents (which aid in stimulating the production of more red blood cells) also increases. Hence, the aforementioned factors are expected to boost market growth over the forecast period. However, stringent regulatory guidelines to obtain product approvals and the adverse side effects of ESAs are expected to hamper the market growth.
